Stable clone production for anti-EBV monoclonal antibodies
Active Awarded Last action
- Contract number
- 75N91023F00020
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,237,758
Award facts
- Contract value 100% obligated
- $3,237,758.00 Current and potential, with all options
- Completion date 78% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $2,091,048 | |
| Terminate for Convenience | -$21,882 | |
| Terminate for Convenience | $0 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,168,592 |
About this award
The National Cancer Institute awarded a $3.24M delivery order contract to Leidos Biomedical Research Inc. for stable clone production of anti-Epstein-Barr virus monoclonal antibodies. The contract, which commenced on September 1, 2023, and is scheduled for completion by September 10, 2027, employs a cost-plus-fixed-fee pricing structure without set-aside designation. Work will be performed at Leidos Biomedical Research Inc.'s facility in Frederick, Maryland, where the company operates as a Federally Funded Research and Development Center contractor providing comprehensive biomedical research and facilities support to the National Cancer Institute and National Institutes of Health.
Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings Inc., specializes in advanced therapeutic development and biomedical research support, with demonstrated expertise in monoclonal antibody production, gene therapy development, and infectious disease research. The Frederick National Laboratory for Cancer Research, where this work will be conducted, has established capabilities in genetic engineering, immunological research, and manufacturing of therapeutic agents. This delivery order aligns with the National Cancer Institute's broader research mission and represents continuation of the company's long-standing role in supporting critical cancer research and therapeutic development initiatives.
Quick answers
Who was awarded contract 75N91023F00020?
75N91023F00020 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 1, 2023.
How much is contract 75N91023F00020 worth?
The government has obligated $3,237,758 on 75N91023F00020.
Is contract 75N91023F00020 an order under another contract?
Yes. 75N91023F00020 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91023F00020 competed?
The extent of competition for 75N91023F00020 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award